Abstracts tagged "Behçet’s Syndrome"

Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 1074 • ACR Convergence 2025
Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Shahrzad Abdollahi² and Irene Tan⁴, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Racial/ethnic disparities in Behçet’s disease (BD) outcomes are largely undocumented in the United States. Given known differences in disease expression across populations globally, we…
Abstract Number: 2544 • ACR Convergence 2025
Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
ruken Alcin Bayraktar¹, Yasemin Kayadibi², Aysenur Kahveci², Sinem Nihal Esatoglu³, Ibrahim Adaletli², Yesim Ozguler³, Melike Melikoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Several studies have demonstrated increased venous wall thickness (VWT) in patients with Behçet’s syndrome (BS) compared to healthy and diseased control groups. Ultrasonographic measurement…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 2543 • ACR Convergence 2025
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Mustafa Erdogan¹, Koray Tascilar², Yagmur Ersoya³, Alp Ozcan⁴, Mert Gurcan⁴, Talal Ammar⁴, Sinem Nihal Esatoglu⁵, Yesim Ozguler⁵, Gulen Hatemi⁵ and Hasan Yazici⁶, ¹Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Rheumatology / Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine ³, Rheumatology and Immunology, Erlangen, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Academic Hospital, Istanbul, Turkey
Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…
Abstract Number: 0272 • ACR Convergence 2025
Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Elena Aurrecoechea⁵ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital Sierrallana, CANTABRIA, Spain
Background/Purpose: Ocular involvement is a potential severe complication of Behçet’s Disease (BD). The traditional classification, by the International Study Group (ISG, 1990) requires the mandatory…
Abstract Number: 2541 • ACR Convergence 2025
Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Toshihiro Tono⁴, Mitsuhiro Takeno⁵ and Izumi Kawachi⁶, ¹Nobuhara Clinic, Tokyo, Japan, ²Teikyo University School of Medicine, ³-¹²-¹ ????????????¹³⁰⁸, Japan, ³Tokyo Medical University, Tokyo, Japan, ⁴Kitasato University School of Medicine, Kanagawa, Japan, ⁵Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Japan, ⁶Niigata University Graduate School of Medicine and Dental Sciences and Niigata University Brain Institute, Niigata, Japan
Background/Purpose: Chronic progressive neuro-Behçet’s disease (CPNB) is characterized by progressive deterioration leading to disability and death. It has been appreciated that methotrexate (MTX) has beneficial…
Abstract Number: 0254 • ACR Convergence 2025
Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis
Justin Riley Lam¹, Emmanuel Otabor², Laith Alomari², Michael Hamilton², Maxim Barnett², Shahrzad Abdollahi³ and Irene Tan⁴, ¹Albert Einstein Medical Center, Philadelphia, PA, ²Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA, ⁴Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: MAGIC syndrome, a rare overlap of relapsing polychondritis (RP) and Behçet’s disease manifestations, remains poorly characterized compared to isolated RP. Behçet’s-associated features such as…
Abstract Number: 2540 • ACR Convergence 2025
Monocyte-to-High-Density Lipoprotein Cholesterol Ratio as a Clinical Marker of Gastrointestinal Involvement in Behçet Syndrome
Hansun Song, Seong-Ryul Kwon and Mie Jin Lim, College of Medicine, Inha University, Incheon, Republic of Korea
Background/Purpose: Behçet syndrome (BS) is a chronic multisystem vasculitis marked by recurrent mucocutaneous and ocular inflammation, and in a subset of patients, gastrointestinal (GI) involvement.…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 2538 • ACR Convergence 2025
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Carmen Lasa Teja⁵, Elena Aurrecoechea⁶, Diana Prieto-Peña⁷ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ⁶Hospital Sierrallana, CANTABRIA, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
Abstract Number: 0240 • ACR Convergence 2025
Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Amir Razmjou¹, Alexandra Klomhaus², David Kellner³, Meika Fang⁴, Michael Weisman⁵ and John FitzGerald³, ¹UCLA / Veterans Affairs, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the…
Abstract Number: 2536 • ACR Convergence 2025
High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
Mateus Augusto Rangel Nunes, Carlos Teixeira, Laurie Kumano, Gabriela Gutierrez, Vitor Grotti, Ana Paula Toledo Del Rio, Ibsen Coimbra, Alisson Pugliesi and Zoraida Sachetto, UNICAMP, Campinas, Brazil
Background/Purpose: Behçet's disease (BD) is a chronic systemic inflammatory disease classified as a variable vessel vasculitis of unknown etiology. It is marked by recurrent oral…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 2534 • ACR Convergence 2025
Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Koichi Sugihara¹, Risa Wakiya², Hiromi Shimada¹, Taichi Miyagi³, Yusuke Ushio³, Mao Mizusaki¹, Kanako Chujo³, Naoto Manabe³, Mayuko Wada¹, Shusaku Nakashima¹ and Hiroaki Dobashi¹, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University, Ota City Tokyo, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: The associations of HLA-B51 and HLA-A26 with the onset of Behçet’s disease (BD) are well established. Although BD manifests with a variety of clinical…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].